Literature DB >> 16792576

Mechanisms of allergen specific immunotherapy--T-cell tolerance and more.

M Jutel1, M Akdis, K Blaser, C A Akdis.   

Abstract

Specific immune suppression and induction of tolerance are essential processes in the regulation and circumvention of immune defence. The balance between allergen-specific T-regulatory (Treg) cells and T helper 2 cells appears to be decisive in the development of allergic and healthy immune response against allergens. Treg cells consistently represent the dominant subset specific for common environmental allergens in healthy individuals. In contrast, there is a high frequency of allergen-specific T helper 2 cells in allergic individuals. A decrease in interleukin (IL)-4, IL-5 and IL-13 production by allergen-specific CD4+ T cells due to the induction of peripheral T cell tolerance is the most essential step in allergen-specific immunotherapy (SIT). Suppressed proliferative and cytokine responses against the major allergens are induced by multiple suppressor factors, such as cytokines like IL-10 and transforming growth factor (TGF)-beta and cell surface molecules like cytotoxic T lymphocyte antigen-4, programmed death-1 and histamine receptor 2. There is considerable rationale for targeting T cells to increase efficacy of SIT. Such novel approaches include the use of modified allergens produced using recombinant DNA technology and adjuvants or additional drugs, which may increase the generation of allergen-specific peripheral tolerance. By the application of the recent knowledge in Treg cells and related mechanisms of peripheral tolerance, more rational and safer approaches are awaiting for the future of prevention and cure of allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792576     DOI: 10.1111/j.1398-9995.2006.01175.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  27 in total

1.  Prevention and treatment of allergic inflammation by an Fcγ-Der f2 fusion protein in a murine model of dust mite-induced asthma.

Authors:  Li-hui Lin; Ping Zheng; John W M Yuen; Juan Wang; Juan Zhou; Cun-quan Kong; Xia Peng; Jia Li; Li Li
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

Review 2.  [Immunological principles of allergen-specific immune therapy].

Authors:  K Blaser
Journal:  HNO       Date:  2008-08       Impact factor: 1.284

3.  Are we getting enough allergens?

Authors:  Allan Linneberg
Journal:  Int Arch Allergy Immunol       Date:  2008-06-03       Impact factor: 2.749

4.  Clinico-immunologic study on immunotherapy with mixed and single insect allergens.

Authors:  Deepsikha Srivastava; Bhanu P Singh; Naveen Arora; Shailendra Nath Gaur
Journal:  J Clin Immunol       Date:  2009-06-16       Impact factor: 8.317

Review 5.  [Immunologic control parameters during specific immunotherapy].

Authors:  H Ott; M Wosnitza; H F Merk
Journal:  Hautarzt       Date:  2008-07       Impact factor: 0.751

Review 6.  Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences.

Authors:  L Li; V Boussiotis
Journal:  Chem Immunol Allergy       Date:  2008

7.  [Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].

Authors:  L Klimek; J Willers; P Schendzielorz; T M Kündig; G Senti
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

8.  Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.

Authors:  M Rosewich; J Schulze; O Eickmeier; T Telles; M A Rose; R Schubert; S Zielen
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

9.  Nature of regulatory T cells in the context of allergic disease.

Authors:  Cevdet Ozdemir; Mübeccel Akdis; Cezmi A Akdis
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

10.  Sublingual immunotherapy in allergic asthma: Current evidence and needs to meet.

Authors:  Cristoforo Incorvaia; Gian Galeazzo Riario-Sforza; Stefano Incorvaia; Franco Frati
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.